Showing results (41-50 of 94) with videos related to

Sort By:
Pageof 10
Immunotargets and Therapy|May 20, 2026
Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer - A Post Hoc Analysis of METIMMOX Trial DataSebastian Meltzer, Silje Sjåvik Landmark, Jūratė Šaltytė Benth, et al.
BMC Cancer|November 22, 2012
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximabJanne B Kjersem, Tone Ikdahl, Tormod Guren, et al.
Clinical Colorectal Cancer|January 1, 2025
Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal CancerJulian Hamfjord, Tormod Kyrre Guren, Bengt Glimelius, et al.
Plos One|February 6, 2014
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII StudyLine S Tarpgaard, Tormod K Guren, Bengt Glimelius, et al.
Oncotarget|October 15, 2016
Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancerMaria Thomsen, Christian Kersten, Halfdan Sorbye, et al.
International Journal of Cancer|May 7, 2021
Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancerJulian Hamfjord, Tormod Kyrre Guren, Bengt Glimelius, et al.
Acta Oncologica (Stockholm, Sweden)|January 12, 2020
Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosisLuís Nunes, Kristine Aasebø, Lucy Mathot, et al.
Medical Oncology (Northwood, London, England)|March 8, 2018
Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)Abir Salwa Ali, Malin Grönberg, Seppo W Langer, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2017
Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation statusMaria Thomsen, Marianne Grønlie Guren, Eva Skovlund, et al.
British Journal of Cancer|June 7, 2018
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcomeMaria Thomsen, Eva Skovlund, Halfdan Sorbye, et al.
Pageof 10